Tag: option-agreement

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

| April 6, 2015 | 0 Comments

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

Continue Reading

MD Anderson, Astellas Pharma sign option agreement for monoclonal antibody drug targeting acute myeloid leukemia

| April 3, 2015 | 0 Comments

( University of Texas M. D. Anderson Cancer Center ) The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

MD Anderson, Astellas Pharma Sign Option Agreement

| April 3, 2015 | 0 Comments

The University of Texas MD Anderson Cancer Center and Astellas Pharma Inc.

Continue Reading

Stem Cell Therapeutics Acquires an Exclusive Option to License Prostate Cancer Stem Cell Assets

| August 9, 2013 | 0 Comments

Stem Cell Therapeutics Corp. , a biopharmaceutical company developing cancer stem cell-related therapeutics, today announced that it has entered into an option agreement to exclusively license worldwide …

Continue Reading